Dendreon elects Dennis Fenton to board
This article was originally published in Scrip
Dendreon, a biotech company developing therapeutics to treat cancer, has appointed Dennis Fenton to its board of directors. Dr Fenton has 30 years' experience of the pharmaceutical and biotech industries, including over two decades at Amgen where he most recently served as executive vice-president for operations and compliance officer until 2008. He is currently a board member of Genelux, Napo Pharmaceuticals, Kythera Biopharmaceuticals and XenoPort.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.